OCI-LY1 Cells
USUSD$500.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | OCI-LY1 is a human diffuse large B-cell lymphoma (DLBCL) cell line derived from an adult patient. It belongs to the germinal center B-cell (GCB) subtype of DLBCL, characterized by its molecular signature that mirrors normal germinal center B cells. This classification is supported by gene expression profiling, which has shown that OCI-LY1 clusters with GCB-DLBCLs, a group typically associated with a better prognosis compared to activated B-cell (ABC) DLBCL. The cell line maintains surface expression of B-cell markers and exhibits hallmarks of DLBCL including a high proliferation rate and chromosomal abnormalities consistent with aggressive lymphoma behavior. OCI-LY1 has been a valuable model in the study of genetic heterogeneity and oncogenic signaling in DLBCL. Genomic studies have identified recurrent mutations in this line, including alterations in genes regulating chromatin remodeling, apoptosis, and B-cell receptor signaling pathways. Notably, OCI-LY1 does not harbor constitutive NF-κB pathway activation, a feature that distinguishes it from ABC-DLBCL cell lines and aligns it with the GCB molecular subtype. This makes it particularly useful for investigating mechanisms of lymphomagenesis and drug responses that are independent of NF-κB signaling. Furthermore, it has been used in immunogenetic studies including HLA typing, which is critical for exploring tumor immunogenicity and neoantigen presentation in the context of cancer immunotherapy. In culture, OCI-LY1 cells exhibit suspension growth and are amenable to both in vitro and in vivo experimentation, including xenograft studies. They retain clonotypic immunoglobulin rearrangements, confirming their derivation from a single B-cell clone. Their stable growth properties and genetic profile make them a reliable tool for preclinical testing of targeted therapies, particularly those aimed at epigenetic modulators, PI3K pathway inhibitors, and agents inducing DNA damage responses. |
|---|---|
| 生物體 | Human |
| 組織 | Bone marrow |
| 疾病 | Diffuse large B-cell lymphoma |
| 同義詞 | OCI-L years1, OCI-ly1, OCI-L years-1, OCI-Ly-1, Oci-Ly-1, OCI-Ly 1, OCI-Ly01, OCI Ly1, Ly1, L years1 |
特徵
| 年齡 | 44 years |
|---|---|
| 性別 | Male |
| 生長特性 | Supsension |
監管數據
| 引用 | OCI-LY1 (Cytion catalog number 305846) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_1879 |
生物分子資料
| 突變譜 |
|---|
處理方式
| 培養基 | IMDM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 25 mM HEPES, w: 1.0 mM Sodium pyruvate, w: 3.024 g/L NaHCO3 (Cytion article number 820800a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% heat-inactivated FBS |
| 倍增時間 | 50 hours |
| 播種密度 | 0.5 to 2 x 106 cells/ml |
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305846-270126 | 分析證明書 | 20. Feb. 2026 | 305846 |